•PECAA debuts private label 1-day contact lenses developed by CooperVision•Low vision rehab less effective in patients with hearing loss•Neuvasq highlights novel antibody approach for restoring blood-retina barrier in wet AMD and DME•Metformin may slow postoperative PCO•Lineage reports positive 36-month findings on GA cell therapy•PECAA debuts private label 1-day contact lenses developed by CooperVision•Low vision rehab less effective in patients with hearing loss•Neuvasq highlights novel antibody approach for restoring blood-retina barrier in wet AMD and DME•Metformin may slow postoperative PCO•Lineage reports positive 36-month findings on GA cell therapy
HEADLINES
FEATURED
Decision follows company’s challenge to its third rejected package of ONS-5010 / LYTENAVA (bevacizumab-vikg); fourth submission expected in June.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
